Rami Levin, Chief Executive Officer, and Xiaofang Wang, Chief Technology Officer will give an update on the company’s latest advances in its first-in-class T-MSC (IMS001)cell therapy at 2022 Cell & Gene Meeting On the MESA.
Rudolf Jaenisch, a Professor of Biology at MIT and a founding member of the Whitehead Institute for Biomedical Research, joins ImStem Biotechnology as Member of Scientific Advisory Board.